Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
[212Pb] VMT-Ξ±-NET
Perspective Therapeutics
Neuroendocrine Tumors
1 trial -
[225Ac]Ac-AKY-1189 (therapeutic)
Aktis Oncology
Urothelial Carcinoma Bladder
1 trial -
[225Ac]Ac-AKY-2519 (therapeutic)
Aktis Oncology
Castration Resistant Metastatic Prostate Cancer
1 trial -
[68Ga]Ga-PentixaFor
CERO THERAPEUTICS HOLDINGS, INC.
triple-negative breast cancer
1 trial -
[F18]-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18F]fluorodibenzo[b,d]thiophene 5,5-dioxide)
BRIGHT MINDS BIOSCIENCES INC.
Tobacco Use Disorder
1 trial -
[^14C]-alisertib
Takeda
Advanced Solid Tumors
1 trial -
administration of UI018
United Therapeutics Europe Ltd
Hyperlipemia, Mixed
1 trial -
an inactivated whole virion H5N1 vaccine, adjuvanted
Sinovac Research and Development Co.,
Influenza
1 trial -
anle138b (TEV-56286)
Teva Pharma GmbH
Healthy Volunteers
1 trial -
anti CD19 CAR NK cells
The First People's Hospital of Lianyungang
Antisynthetase Syndrome
1 trial -
anti-CD123 CAR-T treatment
Nanjing Legend Biotech Co.
Acute Leukemia
1 trial -
anti-CD19 CAR NK
Chongqing Precision Biotech Co., Ltd
NHL
1 trial -
anti-CD19 CAR-T
The First People's Hospital of Lianyungang
B-cell Adult Acute Lymphoblastic Leukemia
1 trial -
anti-CD19 allo-CAR-T cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Relapsed Adult ALL
1 trial -
anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells
The First People's Hospital of Lianyungang
Relapsed/refractory Lymphoma
1 trial -
anti-CD19-CAR-T cells
Chongqing Precision Biotech Co., Ltd
Systemic Lupus Erythematosus
1 trial -
autologous ET1402L1-CART cells
AEON Biopharma
Hepatocellular Carcinoma
1 trial -
balapiravir [RO4588161]
Hoffmann-La Roche
Dengue
1 trial -
givosiran (ALN-AS1)
Alnylam Netherlands B.V.
Acute Intermittent Porphyria
1 trial -
hCD19.IL15.CAR-iNKT
The First People's Hospital of Lianyungang
Acute Lymphoblastic Leukemia
1 trial -
high-dose Group ACYW135X Meningococcal Conjugate Vaccine
Sinovac Research and Development Co.,
Meningococcal Meningitis
1 trial -
high-fat diet groupοΌAD16 20mgοΌ
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Alzheimer Disease
1 trial -
iC9.GD2.CAR.IL-15 T Infusion
United Therapeutics Europe Ltd
Lung Cancer
1 trial -
iC9.GD2.CAR.IL-15 T-cells
United Therapeutics Europe Ltd
Neuroblastoma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources